Hereditary transthyretin amyloidosis is a fatal autosomal dominant disorder characterized by deposition of transthyretin amyloid into the peripheral nervous system, heart, kidney, and gastrointestinal tract.

Previous treatments using liver transplantation and small molecule stabilizers were not effective in stopping disease progression.

Inotersen, a modified antisense oligonucleotide, which acts by reducing the production of transthyretin.

Demonstrated to improve disease course and quality of life in early hereditary transthyretin amyloidosis polyneuropathy in a 15-month Phase III study.

Trade name Tegsedi.

Administered subcutaneously.

Associated with thrombocytopenia and glomerulonephritis.

Leave a Reply

Your email address will not be published. Required fields are marked *